All Web Images Videos News
Settings
Appearance
Site Icons
Font Size
Font
General
Infinite Scroll
Open Links in a New Tab
Safe Search
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
MSN - Feb 15, 2025
SVP of Galderma: “We are seeing a new consumer emerge”
Cosmetics Design Europe - Feb 07, 2025
Galderma posts 9.2% sales growth in first nine months of 2024
Reuters - Oct 23, 2024
Galderma Bets on Skin Drug to Turn Around Pharma Business
WSJ - Nov 28, 2024
Bellatox Boutique Wins Top Injector Practice and Top 1% Galderma Account in the Aesthetic Everything® Awards
EIN News - Feb 15, 2025
(Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Business Wire - Feb 14, 2025
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)
Business Wire - Jan 31, 2025
Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines
Business Wire - Jan 31, 2025
(Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
Business Wire - Dec 12, 2024
Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss
Business Wire - Jan 21, 2025
More results